In youths with new-onset type 1 diabetes, intensive glucose control for 24 months did not appear to prevent the decline in residual C-peptide secretion (NEJM)
Diabetes News
Tag: C-peptide
How low is really low? Comparison of two C-peptide assays to establish residual C-peptide production in type 1 diabetes
The IRMA provided the lowest threshold for quantification of serum C-peptide. LoQ of commercially available assays should be established in-house before applying them in research studies and clinical trials in which low C-peptide levels have clinical or scientific relevance (Diabetic Medicine)
Reappearance of C-Peptide During the Third Trimester of Pregnancy in Type 1 Diabetes: Pancreatic Regeneration or Fetal Hyperinsulinism?
First maternal C-peptide appearance at 34 weeks was associated with midtrimester hyperglycemia, elevated cord blood C-peptide, and high rates of neonatal complications. This suggests transfer of C-peptide from fetal to maternal serum and is inconsistent with pregnancy-related β-cell regeneration (Diabetes Care)
Exenatide ER in patients with Type 1 diabetes with and without residual insulin production
Treatment with exenatide ER may have short‐term benefits in some individuals with T1D who are overweight or with detectable levels of C‐peptide, but short term improvements were not sustained (Diabetes, Obesity and Metabolism)
Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide
The glucagon response to an MMTT in people with long-standing type 1 diabetes is not reduced by the presence of residual beta cells. The reduction of GLP-1 responses according to residual C-peptide levels suggests specific regulatory pathways (Diabetologia)
C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase
These data support two clear phases of C-peptide decline: an initial exponential fall over a 7-year period, followed by a prolonged stabilization where C-peptide levels no longer decline. Understanding the pathophysiological and immunological differences between these two phases will give crucial insights into understanding β-cell survival (Diabetes Care)
Metabolic risk profiles in diabetes stratified according to age at onset, islet autoimmunity and fasting C-peptide
Our results demonstrate that fasting C-peptide and GADab status, but not age at onset, define groups of patients with diabetes with clinically relevant differences in glycaemic control and cardiometabolic risk (Diabetes Research and Clinical Practice)
A Practical Review of C-Peptide Testing in Diabetes
We explore the potential uses of c-peptide measurement in clinical practice (Diabetes Therapy)
C-peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry
In youth with T2D, a decline in C-peptide is associated with deterioration of metabolic control and the need for insulin treatment. C-peptide levels decrease over time. However, even insulin-treated patients with 6 or more years of T2D and elevated HbA1c levels retain substantial endogenous insulin secretion (Pediatric Diabetes)
Urinary C-Peptide/Creatinine Ratio Can Distinguish Maturity-Onset Diabetes of the Young from Type 1 Diabetes in Children and Adolescents
We showed that the UCPCR and fasting C-peptide levels in children and adolescents can distinguish patients with MODY from patients with T1DM with high specificity and sensitivity (Hormone Research in Paediatrics)
Biomarkers related to severe hypoglycaemia and lack of good glycaemic control in ACCORD
C-peptide and islet autoantibodies may serve as biomarkers to predict the risk of severe hypoglycaemia during intensification of type 2 diabetes treatment (Diabetologia)
Glycosmedia is also available as an App: